Streptomyces Patents (Class 435/252.35)
-
Publication number: 20130011891Abstract: The invention provides non-naturally occurring microbial organisms having a butadiene or crotyl alcohol pathway. The invention additionally provides methods of using such organisms to produce butadiene or crotyl alcohol.Type: ApplicationFiled: June 19, 2012Publication date: January 10, 2013Inventors: Mark J. Burk, Anthony P. Burgard, Robin E. Osterhout, Jun Sun, Priti Pharkya
-
Publication number: 20130011828Abstract: The present invention relates to the use of one or more cas genes for modulating resistance in a cell against a target nucleic acid or a transcription product thereof.Type: ApplicationFiled: June 6, 2012Publication date: January 10, 2013Inventors: Rodolphe Barrangou, Patrick Boyaval, Christophe Fremaux, Philippe Horvath, Dennis Romero
-
Publication number: 20130014293Abstract: The present invention relates to variants of a parent xylanase. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: March 2, 2011Publication date: January 10, 2013Applicants: NOVOZYMES A/S, NOVOZYMES, INC.Inventors: Janine Lin, Jung Ye, Aubrey Jones, Suzanne Otani, Tia Heu, Pierre Cassland, Esben Friis
-
Publication number: 20130011882Abstract: Disclosed are compositions comprising variants of alpha-amylase that have alpha-amylase activity and which exhibit altered properties relative to a parent AmyS-like alpha-amylase from which they are derived. The compositions comprise an additional enzyme such as a phytase. Also disclosed are methods of using the compositions, and kits related thereto.Type: ApplicationFiled: May 15, 2012Publication date: January 10, 2013Applicant: DANISCO US INC.Inventors: LUIS G. CASCÃO-PEREIRA, JAMES T. KELLIS, JR., BRADLEY A. PAULSON, SCOTT D. POWER, SANDRA W. RAMER, VIVEK SHARMA, ANDREW SHAW, JAYARAMA K. SHETTY, DONALD E. WARD
-
Publication number: 20130005637Abstract: Proteases encompassing an amino acid sequence that is at least 70% identical to the amino acid sequence indicated in SEQ ID NO. 1 over its entire length, and exhibit the amino acid substitution I21V in the count in accordance with SEQ ID NO. 1, resp. agents that encompass such proteases, display very good cleaning performance on protease-sensitive stains.Type: ApplicationFiled: March 10, 2011Publication date: January 3, 2013Applicant: HENKEL AG & CO. KGAAInventors: Petra Siegert, Ulrich Schwaneberg, Ronny Martinez, Marion Merkel, Astrid Spitz, Susanne Wieland, Hendrik Hellmuth, Karl-Heinz Maurer
-
Publication number: 20130005012Abstract: In vivo methods for production of styrene via a recombinant host cell can include cell expression of at least one polynucleotide encoding a polypeptide having cinnamic acid decarboxylase activity, and at least one polynucleotide encoding a polypeptide having phenylalanine ammonia lyase activity.Type: ApplicationFiled: June 22, 2012Publication date: January 3, 2013Applicant: PHYTOGENE, INC.Inventor: Xiaodan Yu
-
Publication number: 20130005029Abstract: Described are variants (mutants) of a parent alpha-amylase having alpha-amylase activity and exhibiting altered properties relative to the parent alpha-amylase, and methods of use, thereof.Type: ApplicationFiled: July 2, 2012Publication date: January 3, 2013Applicant: Danisco US Inc., Genencor DivisionInventors: Luis G. CASCAO-PEREIRA, Claudine Chang, Clement Choy, James T. Kellis, JR., Brain E. Jones, Melodie Estabrook, Marc Kolkman, Chris Leeflang, Casper Vroemen, Walter Weyler
-
Publication number: 20120328622Abstract: The invention provides BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and polynucleotides encoding BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: ApplicationFiled: June 15, 2012Publication date: December 27, 2012Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Catherine Defrenne, Christine Delmelle, Jean-Louis Ruelle
-
Publication number: 20120331589Abstract: The subject invention includes methods and plants for controlling lepidopteran insects, said plants comprising Cry1Fa and Cry1Da core toxin containing proteins in combination to delay or prevent development of resistance by the insect(s).Type: ApplicationFiled: December 16, 2010Publication date: December 27, 2012Applicant: DOW AGROSCIENCES LLCInventors: Thomas Meade, Kenneth Narva, Nicholas P. Storer, Joel J. Sheets, Aaron T. Woosley, Stephanie L. Burton
-
Publication number: 20120329104Abstract: A modified microorganism having enhanced xylose utilization, an expression vector for constructing the modified microorganism, and a method of producing a chemical using the same are disclosed.Type: ApplicationFiled: June 27, 2012Publication date: December 27, 2012Applicants: SEOUL UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SAMSUNG ELECTRONICS CO., LTD.Inventors: Jae Young KIM, Hyun Min KOO, Young kyoung PARK, Jae Chan PARK, Sung Min PARK, Jin Ho SEO, Yong Cheol PARK
-
Publication number: 20120329119Abstract: The invention provides non-naturally occurring microbial organisms having a propylene pathway. The invention additionally provides methods of using such organisms to produce propylene.Type: ApplicationFiled: June 19, 2012Publication date: December 27, 2012Inventors: Anthony P. Burgard, Robin E. Osterhout, Jun Sun, Priti Pharkya, Mark J. Burk
-
Publication number: 20120331588Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: August 30, 2012Publication date: December 27, 2012Applicant: Novozymes A/SInventors: Alfredo Lopez de Leon, Michael Rey
-
Publication number: 20120321657Abstract: Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A streptococcus (GAS). Immunogenic compositions provided herein are multivalent and comprise a plurality of immunogenic peptides or fusion polypeptides comprising the immunogenic peptides that induce an immune response against GAS. The immunogenic compositions provided herein induce an immune response against the GAS serotypes represented by an immunogenic peptide (derived from an M protein or Spa protein) comprised within the immunogenic composition and also induce an immune response against serotypes that are unrepresented by any immunogenic peptide included in the immunogenic composition. Methods for using the compositions for inducing an immune response against GAS and for treating or reducing the likelihood of occurrence of a GAS infection are also provided.Type: ApplicationFiled: June 15, 2012Publication date: December 20, 2012Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventor: James B. Dale
-
Publication number: 20120322148Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic plants and animals.Type: ApplicationFiled: May 3, 2012Publication date: December 20, 2012Applicant: Intrexon CorporationInventors: Subba Reddy Palli, Marianna Zinovjevna Kapitskaya, Dean Ervin Cress
-
Publication number: 20120321628Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.Type: ApplicationFiled: June 8, 2012Publication date: December 20, 2012Applicant: Genentech, Inc.Inventors: Ralph H. Schwall, Kelly H. Tabor
-
Publication number: 20120321614Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies.Type: ApplicationFiled: April 24, 2012Publication date: December 20, 2012Applicants: Pfizer, Inc., Amgen Fremont Inc.Inventors: Neil R. Michaud, Shama Kajiji, Gary Borzillo, Vahe Bedian, Kevin Coleman, Larry L. Green, Xiao-Chi Jia
-
Publication number: 20120321747Abstract: Proteases derived from Nocardiopsis dassonvillei subsp. dassonvillei DSM 43235, Nocardiopsis prasina DSM 15649, Nocardiopsis prasina (previously alba) DSM 14010 Nocardiopsis sp. DSM 16424, Nocardiopsis alkaliphila DSM 44657 and Nocardiopsis lucentensis DSM 44048, as well as homologous proteases; their recombinant production in various hosts, including transgenic plants and non-human animals, and their use in animal feed and detergents. The proteases are acid-stable, alkali-stable, and/or thermostable.Type: ApplicationFiled: June 7, 2012Publication date: December 20, 2012Applicant: NOVOZYMES A/SInventors: Soren Flensted Lassen, Carsten Sjoeholm, Peter Rahbek Oestergaard, Morten Fischer
-
Publication number: 20120321746Abstract: Proteases derived from Nocardiopsis dassonvillei subsp. dassonvillei DSM 43235, Nocardiopsis prasina DSM 15649, Nocardiopsis prasina (previously alba) DSM 14010 Nocardiopsis sp. DSM 16424, Nocardiopsis alkaliphila DSM 44657 and Nocardiopsis lucentensis DSM 44048, as well as homologous proteases; their recombinant production in various hosts, including transgenic plants and non-human animals, and their use in animal feed and detergents. The proteases are acid-stable, alkali-stable, and/or thermostable.Type: ApplicationFiled: June 7, 2012Publication date: December 20, 2012Applicant: NOVOZYMES A/SInventors: Soren Flensted Lassen, Carsten Sjoeholm, Peter Rahbek Ostergaard, Morten Fischer
-
Publication number: 20120321619Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 29 kDa C4.4a polypeptide, which is over expressed in several tumors, e.g. lung, colorectal, pancreas, prostate, renal and breast cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of C4.4a in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: December 8, 2010Publication date: December 20, 2012Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Lars Linden, Yong-Jiang Cao, Gabriele Leder, Beatrix Stelte-ludwig, Axel Harrenga, Ricarda Finnern, Frank Dittmer, Anke Mayer-Bartschmid, Juergen Franz, Simone Greven, Jörg Willuda, Jan Tebbe
-
Publication number: 20120321626Abstract: The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.Type: ApplicationFiled: May 16, 2012Publication date: December 20, 2012Applicant: FABION PHARMACEUTICALS, INC.Inventor: Hongxing Zhou
-
Publication number: 20120316101Abstract: The present invention relates to a polypeptide capable of specifically targeting apoptotic cells undergoing apoptosis and a use thereof. More particularly, it relates to an isolated polypeptide consisting of the sequence (I): Cys-X1-Val-Ala-Pro-X2 (I), wherein X1 is an amino acid with polar uncharged side chain and X2 is an amino acid with positive charged side chain and targeting apoptotic cells, a composition for detection of apoptotic cells comprising the same as an effective ingredient, a composition for drug delivery comprising the same as an effective ingredient, a composition for imaging comprising the same as an effective ingredient and the like. Accordingly, the peptide of the present invention may be useful for detection of apoptotic cells, as well as detection and imaging of apoptotic cells in tumor tissue, apoptotic myocardial cells in myocardial infarction tissue, apoptotic nerve cells in stroke tissue and arteriosclerosis site, and targeted drug delivery thereto.Type: ApplicationFiled: May 9, 2012Publication date: December 13, 2012Applicant: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Byung Heon Lee, In San Kim
-
Publication number: 20120317681Abstract: The subject invention includes methods and plants for controlling lepidopteran insects, said plants comprising a Cry1Fa insecticidal protein and a Cry1Ca insecticidal protein, in combination, to delay or prevent development of resistance by the insect(s).Type: ApplicationFiled: December 16, 2010Publication date: December 13, 2012Inventors: Thomas Meade, Kenneth Narva, Nicholas P. Storer, Joel J. Sheets, Aaron T. Woosley, Stephanie L. Burton
-
Publication number: 20120317682Abstract: The subject invention includes methods and plants for controlling lepidopteran insects, said plants comprising a Vip3Ab insecticidal protein in combination with a Cry 1Fa insecticidal protein to delay or prevent development of resistance by the insect(s).Type: ApplicationFiled: December 16, 2010Publication date: December 13, 2012Applicant: Dow Agrosciences LLCInventors: Thomas Meade, Kenneth Narva, Nicholas P. Storer, Joel J. Sheets, Aaron T. Woosley, Stephanie L. Burton
-
Publication number: 20120315267Abstract: The present invention relates to antibodies which multiple antigen specificities and their use in treating human diseasesType: ApplicationFiled: February 9, 2011Publication date: December 13, 2012Applicant: GLAXOSMITHKLINE LLCInventors: Stephanie Jane Clegg, Eric Dobrzynski, Jonathan Henry Ellis, Volker Germaschewski, Alexis Paul Godillot, Zdenka Ludmila Jonak, Alan Peter Lewis, John Richard White
-
Publication number: 20120309059Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: ApplicationFiled: July 31, 2012Publication date: December 6, 2012Applicants: NOVOZYMES, INC., NOVOZYMES A/SInventors: Paul Harris, Elena Vlasenko, Elizabeth Zaretsky, Marcus Sakari Kauppinnen, Sarah Teter, Kimberly Brown
-
Publication number: 20120308594Abstract: The current invention relates to a previously unrecognized clade of HCV genotypes as well as to diagnostic, prophylactic and therapeutic applications of nucleic acids, proteins, and antibodies to said protein, derived of or based on the newly characterized hepatitis C viruses.Type: ApplicationFiled: December 9, 2011Publication date: December 6, 2012Applicant: INNOGENETICSInventors: Erwin Sablon, Wim Quint, Leen-Jan Van Doorn
-
Publication number: 20120311745Abstract: The subject invention includes methods and plants for controlling lepidopteran insects, said plants comprising Cry1Ca insecticidal protein and a Cry1Ab insecticidal protein in combination to delay or prevent development of resistance by the insects.Type: ApplicationFiled: December 16, 2010Publication date: December 6, 2012Applicant: DOW AGROSCIENCES LLCInventors: Thomas Meade, Aaron T. Woosley, Kenneth Narva, Stephanie L. Burton, Nicholas P. Storer, Joel J. Sheets
-
Publication number: 20120309067Abstract: The present invention relates to proteases having at least 75% identity to a protease derived from Thermoascus aurantiacus and comprises at least one modification in the amino acid sequence thereof. These protease variants have improved thermostability. The invention also relates to DNA encoding these proteases, methods of their production, as well as the use thereof.Type: ApplicationFiled: December 10, 2010Publication date: December 6, 2012Applicants: NOVOZYMES NORTH AMERICA, INC., NOVOZYMES A/SInventors: Tomoko Matsui, Allan Noergaard, Thomas Poulsen Agersten, John Matthews
-
Publication number: 20120309918Abstract: The invention relates to a polypeptide having oxidoreductase activity which comprises the amino acid sequence set out in SEQ ID NO: 3 or an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, or a variant polypeptide thereof having 45% or more sequence identity with the sequence of SEQ ID NO: 3. The invention also relates to a process for the production of 2,5-furan-dicarboxylic acid (FDCA) or production of 5-hydroxymethyl-2-furancarboxylic acid (HMF acid).Type: ApplicationFiled: September 2, 2010Publication date: December 6, 2012Applicant: DSM IP ASSETS B.V.Inventors: Harald Johan Ruijssenaars, Nick Johannes Petrus Wierckx, Frank Wouter Koopman, Adrianus Johannes Jozef Straathof, Johannes Hendrik De Winde
-
Publication number: 20120304337Abstract: The invention provides novel ?-endotoxin polypeptides, and variants and fragments thereof, obtained from Bacillus thuringiensis having pesticidal activity against nematodes. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, biopesticide compositions, expression cassettes, and transformed microorganisms and plants comprising a nucleic acid of the invention. These compositions find use in methods for controlling pests, especially plant parasitic nematodes.Type: ApplicationFiled: May 23, 2012Publication date: November 29, 2012Applicant: Pioneer Hi-Bred International, Inc.Inventors: Ute Schellenberger, Jun-Zhi Wei, Genhai Zhu
-
Publication number: 20120301927Abstract: Variants of a Pseudomonas saccharophila G4-forming amylase (PS4) advantageously can catalyze high temperature saccharification to produce maltotetraose syrup from a starch liquefact or granular starch, e.g., derived from cornstarch. The PS4 variants are useful in a process of saccharification of starch that advantageously produces significant amounts of maltotetraose, which can be used downstream in a process of producing a maltotetraose syrup. In one embodiment, a thermostable PS4 variant is provided that can produce about 40% to about 60% by weight maltotetraose, based on total saccharide content.Type: ApplicationFiled: April 8, 2010Publication date: November 29, 2012Applicant: DANISCO US INC.Inventors: Gang Duan, Sung Ho Lee, Ying Qian, Rafael F. Sala, Jayarama Shetty
-
Publication number: 20120301461Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: May 8, 2012Publication date: November 29, 2012Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Laura Orsatti, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
-
Publication number: 20120301497Abstract: Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any strain of P. vivax.Type: ApplicationFiled: August 3, 2012Publication date: November 29, 2012Inventors: Anjali Yadava, Christian F. Ockenhouse
-
Publication number: 20120301469Abstract: Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.Type: ApplicationFiled: November 30, 2010Publication date: November 29, 2012Applicant: Ablynx N.V.Inventors: Erik Depla, Catelijne Stortelers
-
Publication number: 20120295308Abstract: Provided is a modified Family 1 carbohydrate binding module (CBM) comprising amino acid substitutions at one or more of positions 10, 11, 12, 14, 17, 21, 24, 29, 31, 33, and 37, said position determined from alignment of a Family 1 CBM amino acid sequence with SEQ ID NO: 30, and exhibiting from about 50% to about 99.9% amino acid sequence identity to SEQ ID NO: 30. Also provided are modified glycosidase enzymes comprising the modified Family 1 CBM, genetic constructs and genetically modified microbes for expressing the modified Family 1 CBM or modified glycosidase enzyme. The modified Family 1 CBM confers reduced lignin binding and/or increased hydrolysing activity in the presence of lignin to the modified glycosidase enzyme, which may be used in a process for hydrolysing cellulose or hemicellulose in the presence of lignin.Type: ApplicationFiled: February 11, 2011Publication date: November 22, 2012Applicant: IOGEN ENEGY CORPORATIONInventors: John J. Tomashek, Brian R. Scott, Daniel Kolczynski
-
Publication number: 20120294874Abstract: Methods are provided for producing T cell receptor (TCR) like antibodies that recognize peptides displayed in the context of HLA molecules. Antibodies produced by methods provided herein have the specificity of a TCR and can be used as therapeutic, diagnostic and research reagents. Also provided are TCR-like antibodies which recognize Epstein-Barr virus (EBV) peptides displayed in the context of HLA molecules and are useful for the detection and treatment of EBV and EBV-linked diseases.Type: ApplicationFiled: November 18, 2010Publication date: November 22, 2012Inventors: Paul Anthony Macary, Soh Ha Chan, Brendon John Hanson
-
Publication number: 20120295316Abstract: Genetically modified strains of Streptomyces tsukubaensis (S. tsukubaensis) can be used for an improved fermentation process for the preparation of tacrolimus or a salt or derivative thereof by cultivation of these genetically modified strains. Novel genes allowing biosynthesis of allylmalonyl-CoA can be used for polyketide production with allylmalonyl extender unit.Type: ApplicationFiled: July 9, 2010Publication date: November 22, 2012Applicant: LEK PHARMACEUTICALS D.D.Inventors: Hrvoje Petkovic, Enej Kuscer, Stefan Fujs, Gregor Kopitar, Peter Mrak, Gregor Kosec
-
Publication number: 20120295315Abstract: The present invention relates to nulceotide sequences encoding enzymatically active cobalamin-methionine synthase and functional fragments thereof being modified in comparison to the respective wild-type enzyme such that said enzymes show reduced product inhibition by methionine. The present invention also relates to polypeptides being encoded by such nucleotide sequences and host cells comprising such nucleotide sequences. Furthermore, the present invention relates to methods for producing methionine in host organisms by making use of such nucleotide sequences.Type: ApplicationFiled: June 15, 2012Publication date: November 22, 2012Inventors: Oskar Zelder, Wolfgang Grabarse, Corinna Klopprogge, Hartwig Schröder, Stefan Haefner, Anja Knietsch, Andrea Herold
-
Patent number: 8313922Abstract: The present invention relates to an improved process for the production of Daptomycin by fermentation with Streptomyces roseosporus, in the presence of n-decanal or Cuphea oil as sources of the n-decanoyl side chain. These reagents allow to reduce toxicity effects on the bacteria and to avoid the use of solvents in the feeding solution.Type: GrantFiled: July 30, 2009Date of Patent: November 20, 2012Assignee: Antibioticos S.p.A.Inventors: Gianluca Bertetti, Antonella Malcangi, Roberto Muraca, Guido Trione, Alessia Rossi
-
Publication number: 20120289689Abstract: The present invention relates to a recombinant process for the production of truncated or mutated dextransucrases while conserving the enzymatic activity or their specificity in the synthesis of the ?-1,6 bonds. The present invention relates to nucleic acid sequences of truncated or mutated dextransucrases, vectors containing the nucleic acid sequences and host cells transformed by sequences encoding truncated or mutated dextransucrases. In another aspect, the invention concerns a method for producing, in a recombinant manner, truncated or mutated dextransucrases which conserve their enzymatic activity or which conserve their specificity in the synthesis of ?-1,6 bonds and can produce, from saccharose, dextrans with high molar mass and modified rheological properties compared with the properties of dextran obtained with the native enzyme and isomalto-oligosaccharides with a controlled molar mass and dextrans.Type: ApplicationFiled: August 2, 2012Publication date: November 15, 2012Inventors: Pierre F. Monsan, Magali Remaud-Simeon, Gabrielle Potocki-Veronese, Claire Moulis
-
Publication number: 20120288904Abstract: The present invention relates to a method for the production of methionine using modified strains with attenuated transformation of threonine. This can be achieved by reducing threonine transformation into glycine, and/or by reducing its transformation to ?-ketobutyrate. The invention also concerns the modified strains with attenuated transformation of threonine.Type: ApplicationFiled: December 29, 2010Publication date: November 15, 2012Applicant: METABOLIC EXPLORERInventors: Cedric Boisart, Gwenaelle Bestel-Corre, Guillaume Barbier, Rainer Figge
-
Publication number: 20120288585Abstract: The present invention relates to isolated polypeptides having xylanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: December 9, 2010Publication date: November 15, 2012Applicant: NOVOZYMES A/SInventors: Lars Beier, Miguel Duarte Toscano, Esben Peter Friis, Merete Moeller Engelsen, Henrik Lundkvist, Sune Sauer Lobedanz
-
Publication number: 20120289468Abstract: The present invention relates to methods, compositions and kits for preparing FVIII and employing same. Also provided are vWF polypeptides and nucleic acid molecules encoding same.Type: ApplicationFiled: November 12, 2010Publication date: November 15, 2012Applicant: GRIFOLS THERAPEUTICS INC.Inventor: Thomas Barnett
-
Publication number: 20120288490Abstract: The present invention relates to variant lysozymes. The present invention also relates to polynucleotides encoding the variant lysozymes and to nucleic acid constructs, vectors, and host cells comprising the polynucleotide.Type: ApplicationFiled: February 25, 2011Publication date: November 15, 2012Applicant: NOVOZYMES A/SInventor: Leonardo De Maria
-
Publication number: 20120282637Abstract: The present invention relates to a polypeptide or polypeptide complex comprising at least the two amino acid sequences arranged to allow for specific binding to the “receptor for advanced glycation endproducts” (RAGE), one or more nucleic acid(s) coding for the polypeptide or polypeptide complex, a cell producing an antibody against RAGE, a pharmaceutical composition comprising at least one polypeptide or nucleic as defined above, optionally for treating a RAGE-related disease or disorder and a method of diagnosing a RAGE-related disease or disorder.Type: ApplicationFiled: October 8, 2010Publication date: November 8, 2012Applicant: SANOFIInventors: Jochen Huber, Francis Blanche, Tarik Dabdoubi, Fabienne Soubrier, Ingo Focken, Jochen Kruip, Kathrin Heermeier, Christian Lange
-
Publication number: 20120282239Abstract: The present disclosure provides novel mannanase variants which have an amino acid sequence that varies from that of the parent/wild type Trichoderma reesei mannanase, and which have one or more advantageous properties like improved thermo stability; temperature/activity profile; pH/activity profile; specific activity; and pH/protease-sensitivity. The novel mannanase variants are useful and used in alcohol fermentations processes and/or productions, for coffee extraction and the processing of coffee waste, as a supplement to food and feed, for enzyme aided bleaching of paper pulps, as bleaching and/or desizing agent in textile industry, for oil and gas well stimulation by hydraulic fracturing, as detergent, as baking ingredients, for removal of biofilms and in delivery systems, for grain processing or for the processing of renewable resources intended for the production of biological fuels, and in the textile, oil drilling, cleaning, laundering, detergent, and cellulose fiber processing industries.Type: ApplicationFiled: November 24, 2010Publication date: November 8, 2012Applicant: BASF SEInventor: Oliver Kensch
-
Publication number: 20120282271Abstract: The invention provides methods and compositions for modulating hepsin activity and the MSP/Ron pathway, in particular by regulating pro-MSP activation by hepsin.Type: ApplicationFiled: October 21, 2010Publication date: November 8, 2012Applicant: Genentech, Inc.Inventors: Rajkumar Ganesan, Daniel Kirchhofer
-
Publication number: 20120282658Abstract: The present invention relates to variants of a parent alpha-amylase. The present invention also relates to polynucleotides encoding the variants and to nucleic acid constructs, vectors, and host cells comprising the polynucleotides, and methods of using the variant enzymes.Type: ApplicationFiled: January 4, 2011Publication date: November 8, 2012Applicants: NOVOZYMES NORTH AMERICA, INC., NOVOZYMES A/SInventors: Carsten Andersen, Randall Deinhammer, Thomas Agersten Poulsen, Miguel Duarte Toscano, Peter Kamp Hansen, Henrik Friis-Madsen, Anders Viksoe-Nielsen, Signe Eskildsen Larsen, Lars L.H. Christensen
-
Publication number: 20120282177Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer including bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, skin cancer and thyroid cancer.Type: ApplicationFiled: November 2, 2010Publication date: November 8, 2012Inventors: Christian Rohlff, Alasdair Stamps, Jonathan Alexander Terrett
-
Publication number: 20120282264Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.Type: ApplicationFiled: September 24, 2010Publication date: November 8, 2012Inventors: John R. Mascola, Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, Gilad Ofek, Lawrence Shapiro, Jiang Zhu, William R. Schief